ArticleEuropean radiology2012
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
Article in European radiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Liver fat scores do not reflect interventional changes in liver fat content induced by high-protein diets.Scientific reports · 2021Trial
- Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance.PloS one · 2014Trial
- A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction-associated fatty liver disease in newly diagnosed type 2 diabetes patients.Journal of diabetes investigation · 2025Article
- A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients.Frontiers in endocrinology · 2025Article
- Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.Journal of endocrinological investigation · 2021Article
- Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank.Digestive diseases and sciences · 2021Article
- Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting.Journal of clinical medicine · 2020Article
- NAFLD or comorbidities, that is the question.Journal of hepatology · 2020Article
- Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome.Chinese medical journal · 2019Article
- Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.Gene expression · 2019Review
- Article
- Nonalcoholic fatty liver disease: Evolving paradigms.World journal of gastroenterology · 2017Review
- Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop.Journal of nutritional science · 2017Review
- Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population.Clujul medical (1957) · 2016Article
- Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease.World journal of hepatology · 2015Review
- Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI) are clinico-biological scores of steatosis validated in general or selected populations. Serum adiponectin (s-adiponectin) and retinol binding protein 4 (s-RBP4) are adipokines that could predict liver steatosis. We investigated whether the Steatotest, FLI, HSI, s-adiponectin and s-RBP4 could be valid predictors of liver steatosis in type-2 diabetic (T2D) patients.
methodsWe enrolled 220 consecutive T2D patients. Reference standard was 3.0 T (1)H-MR spectroscopy (corrected for T1 and T2 decays). Intraclass correlation coefficients (ICCs), Kappa statistic measures of agreement, receiver operating characteristic (ROC) curves were assessed.
resultsMedian liver fat content was 91 mg triglyceride/g liver tissue (range: 0-392). ICCs among the Steatotest, FLI, HSI, s-adiponectin, s-RBP4 and spectroscopy were low: 0.384, 0.281, 0.087, -0.297 and 0.048. Agreement between scores and spectroscopy was poor (Kappa range: 0.042-0.281). The areas under the ROC curves were low: 0.674, 0.647, 0.637, 0.616 and 0.540. S-adiponectin and s-RBP4 levels were strongly related to the presence of diabetic nephropathy (P = 0.0037 and P = 0.004; Mann-Whitney).
conclusionThe SteatoTest, FLI, HSI, s-adiponectin, s-RBP4 are not valid predictors of steatosis in T2D patients. Clino-biological markers cannot replace (1)H-MR spectroscopy for the assessment of liver fat in this population. KEY POINTS: (1) H-MR spectrosopy can reliably estimate the weight fraction of liver steatosis. Type-2 diabetes provides an interesting model for assessing liver steatosis. Clinico-biological markers seem to be invalid predictors for steatosis in type-2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.